The interaction of 2-phenylisatogen and menadione with rat liver mitochondrial NADH dehydrogenase

The mechanism of inhibition by 2,2'-pyridylisatogen tosylate of NADPH-linked enzyme activities in microsomes isolated from rat liver

Microsomal preparations isolated from rat liver were used to study the action of 2.2'-pyridylisatogen tosylate (PIT) on aniline hydroxylation, cytochrome c reduction and NADPH oxidation. PIT was found to inhibit both the NADPH-dependent (5-100 microM, PIT) and the NADPH-independent (0.05-2.5 mM, PIT) hydroxylation of aniline, but had no significant effect on either the NADPH-dependent oxidation of hexobarbital, or the NADPH-independent hydrolysis of glucose-6-phosphatase. PIT was also found to inhibit cytochrome c reductase competitively (Ki = 35 microM) and to stimulate NADPH oxidation (ED50 = 6.5 microM) PIT and aniline were both found to bind to the microsomal haemoprotein cytochrome P-450 and produce Type II spectral changes. It is proposed that PITs ability to bind to the haemoprotein and its ability to accept electrons from the microsomal NADPH-cytochrome c reductase system leads to the inhibition of aniline hydroxylase activity.

Vitamin K as a regulator of benzo(a)pyrene metabolism, mutagenesis, and carcinogenesis. Studies with rat microsomes and tumorigenesis in mice

Vitamin K3 inhibits the conversion of benzo(a)pyrene to its more polar metabolites in an in vitro rat liver microsomal system. Vitamin K3 also inhibits benzo(a)pyrene metabolism in rat liver fragments and reduces its mutagenicity in the Ames test. Higher concentrations of vitamin K3 are required to comparably reduce benzo(a)pyrene metabolism when the microsomal system has been induced with 3-methylcholanthrene. High pressure liquid chromatography analysis of the products of benzo(a)pyrene metabolism shows a uniform reduction of all the metabolic products. When tumors were induced in ICR/Ha female mice by the intraperitoneal injection of benzo(a)pyrene, those mice given vitamin K3 before or both before and after benzo(a)pyrene had a slower rate of tumor appearance and tumor death rate as compared with those receiving benzo(a)pyrene alone. However, vitamin K1 increased the rate of tumor death while vitamin K deprivation and warfarin decreased the rate of tumor appearance and death in benzo(a)pyrene-injected mice. These studies indicate that vitamin K3 is an inhibitor of aryl hydrocarbon hydroxylase and reduces the carcinogenic and mutagenic metabolites in vitro, and inhibits benzo(a)pyrene tumorigenesis in vivo. That vitamin K1 enhances the benzo(a)pyrene effect while warfarin and vitamin K deficiency inhibit benzo(a)pyrene tumorigenesis indicates that vitamin K1, vitamin K deprivation, or possibly blockade of its metabolic cycle also modulates benzo(a)pyrene metabolism in vivo but by a mechanism or at a site different from the vitamin K3 effect. The vitamin K series should be considered as capable of serving a regulatory function in the metabolism of benzo(a)pyrene and possibly other compounds metabolized through the mixed function oxidase system.